/
/
/

Natco Pharma Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2018Dec 2017Sep 2017Jun 2017Mar 2017Dec 2016Sep 2016Jun 2016Mar 2016Dec 2015Sep 2015Jun 2015Mar 2015Dec 2014Sep 2014Jun 2014Mar 2014Dec 2013Sep 2013Jun 2013Mar 2013Dec 2012Sep 2012
₹735 Cr₹739 Cr₹647 Cr₹1363 Cr₹1329 Cr₹1221 Cr₹475 Cr₹1371 Cr₹1363 Cr₹1068 Cr₹759 Cr₹1031 Cr₹1141 Cr₹898 Cr₹493 Cr₹432 Cr₹885 Cr₹597 Cr₹561 Cr₹377 Cr₹410 Cr₹331 Cr₹355 Cr₹802 Cr₹563 Cr₹455 Cr₹482 Cr₹486 Cr₹492 Cr₹456 Cr₹557 Cr₹544 Cr₹539 Cr₹768 Cr₹562 Cr₹427 Cr₹445 Cr₹578 Cr₹679 Cr₹468 Cr₹340 Cr₹394 Cr₹288 Cr₹243 Cr₹224 Cr₹201 Cr₹195 Cr₹219 Cr₹210 Cr₹184 Cr₹203 Cr₹179 Cr₹173 Cr₹167 Cr₹178 Cr₹180 Cr
₹59 Cr₹78 Cr₹58 Cr₹100 Cr₹62 Cr₹66 Cr₹176 Cr₹64 Cr₹48 Cr₹42 Cr₹37 Cr₹29 Cr₹20 Cr₹29 Cr₹21 Cr₹21 Cr₹34 Cr₹14 Cr₹30 Cr₹38 Cr₹17 Cr₹28 Cr₹31 Cr₹26 Cr₹19 Cr₹22 Cr₹31 Cr₹33 Cr₹21 Cr₹31 Cr₹23 Cr₹40 Cr₹36 Cr₹20 Cr₹11 Cr₹6 Cr₹3 Cr-₹60 L₹6 Cr₹3 Cr₹5 Cr₹40 L₹5 Cr₹2 Cr₹2 Cr₹3 Cr₹7 Cr₹3 Cr₹2 Cr₹10 Cr₹1 Cr₹2 Cr₹4 Cr₹2 Cr₹6 Cr₹88 L
₹794 Cr₹817 Cr₹705 Cr₹1463 Cr₹1391 Cr₹1287 Cr₹651 Cr₹1435 Cr₹1411 Cr₹1110 Cr₹796 Cr₹1061 Cr₹1160 Cr₹927 Cr₹513 Cr₹453 Cr₹919 Cr₹611 Cr₹591 Cr₹415 Cr₹427 Cr₹360 Cr₹386 Cr₹828 Cr₹582 Cr₹477 Cr₹513 Cr₹519 Cr₹513 Cr₹487 Cr₹580 Cr₹584 Cr₹575 Cr₹788 Cr₹574 Cr₹432 Cr₹449 Cr₹577 Cr₹685 Cr₹471 Cr₹346 Cr₹395 Cr₹293 Cr₹245 Cr₹226 Cr₹204 Cr₹203 Cr₹222 Cr₹211 Cr₹194 Cr₹205 Cr₹181 Cr₹176 Cr₹169 Cr₹184 Cr₹181 Cr
₹596 Cr₹662 Cr₹535 Cr₹836 Cr₹816 Cr₹771 Cr₹483 Cr₹613 Cr₹602 Cr₹627 Cr₹535 Cr₹617 Cr₹656 Cr₹600 Cr₹428 Cr₹379 Cr₹529 Cr₹654 Cr₹495 Cr₹341 Cr₹334 Cr₹286 Cr₹303 Cr₹555 Cr₹420 Cr₹357 Cr₹379 Cr₹373 Cr₹323 Cr₹329 Cr₹369 Cr₹343 Cr₹339 Cr₹403 Cr₹293 Cr₹321 Cr₹324 Cr₹350 Cr₹433 Cr₹377 Cr₹276 Cr₹314 Cr₹240 Cr₹197 Cr₹179 Cr₹164 Cr₹160 Cr₹172 Cr₹164 Cr₹155 Cr₹157 Cr₹143 Cr₹135 Cr₹139 Cr₹139 Cr₹142 Cr
₹246 Cr₹205 Cr₹217 Cr₹679 Cr₹633 Cr₹614 Cr₹215 Cr₹868 Cr₹853 Cr₹539 Cr₹305 Cr₹487 Cr₹548 Cr₹368 Cr₹127 Cr₹116 Cr₹430 Cr-₹5 Cr₹132 Cr₹109 Cr₹127 Cr₹105 Cr₹113 Cr₹302 Cr₹190 Cr₹151 Cr₹160 Cr₹168 Cr₹212 Cr₹179 Cr₹232 Cr₹261 Cr₹254 Cr₹403 Cr₹298 Cr₹127 Cr₹140 Cr₹241 Cr₹266 Cr₹108 Cr₹82 Cr₹94 Cr₹66 Cr₹60 Cr₹59 Cr₹53 Cr₹55 Cr₹62 Cr₹59 Cr₹47 Cr₹55 Cr₹45 Cr₹48 Cr₹36 Cr₹51 Cr₹44 Cr
₹13 Cr₹11 Cr₹10 Cr₹13 Cr₹3 Cr₹10 Cr₹4 Cr₹4 Cr₹5 Cr₹6 Cr₹5 Cr₹4 Cr₹4 Cr₹3 Cr₹4 Cr₹4 Cr₹4 Cr₹7 Cr₹5 Cr₹4 Cr₹2 Cr₹4 Cr₹3 Cr₹3 Cr₹4 Cr₹4 Cr₹5 Cr₹6 Cr₹7 Cr₹5 Cr₹6 Cr₹5 Cr₹3 Cr₹3 Cr₹4 Cr₹4 Cr₹4 Cr₹6 Cr₹5 Cr₹4 Cr₹3 Cr₹4 Cr₹4 Cr₹8 Cr₹8 Cr₹9 Cr₹9 Cr₹7 Cr₹7 Cr₹7 Cr₹9 Cr₹10 Cr₹10 Cr₹8 Cr₹8 Cr₹6 Cr
₹186 Cr₹144 Cr₹161 Cr₹614 Cr₹572 Cr₹506 Cr₹164 Cr₹818 Cr₹804 Cr₹478 Cr₹256 Cr₹440 Cr₹500 Cr₹324 Cr₹81 Cr₹70 Cr₹386 Cr-₹50 Cr₹91 Cr₹70 Cr₹91 Cr₹71 Cr₹80 Cr₹271 Cr₹158 Cr₹117 Cr₹129 Cr₹139 Cr₹184 Cr₹152 Cr₹205 Cr₹235 Cr₹232 Cr₹382 Cr₹276 Cr₹107 Cr₹121 Cr₹221 Cr₹248 Cr₹90 Cr₹66 Cr₹78 Cr₹50 Cr₹40 Cr₹38 Cr₹30 Cr₹19 Cr₹44 Cr₹41 Cr₹32 Cr₹38 Cr₹28 Cr₹31 Cr₹22 Cr₹32 Cr₹27 Cr
₹122 Cr₹233 Cr₹140 Cr₹518 Cr₹480 Cr₹406 Cr₹132 Cr₹677 Cr₹669 Cr₹386 Cr₹213 Cr₹369 Cr₹420 Cr₹276 Cr₹62 Cr₹57 Cr₹320 Cr-₹51 Cr₹80 Cr₹65 Cr₹75 Cr₹53 Cr₹63 Cr₹204 Cr₹122 Cr₹93 Cr₹104 Cr₹118 Cr₹143 Cr₹120 Cr₹159 Cr₹182 Cr₹181 Cr₹300 Cr₹217 Cr₹84 Cr₹94 Cr₹176 Cr₹195 Cr₹66 Cr₹48 Cr₹63 Cr₹36 Cr₹29 Cr₹27 Cr₹53 Cr₹14 Cr₹31 Cr₹32 Cr₹25 Cr₹27 Cr₹24 Cr₹21 Cr₹8 Cr₹21 Cr₹20 Cr

Share Price Live Stats

Open (₹)839.00
Volume (₹)3.19 L
High (₹)841.80
Upper Circuit1,005.95
Low (₹)829.00
Lower Circuit670.65
Prev Close838.30
52W High (₹)1,226.80
Price831.05
52W Low (₹)789.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)15010.30 Cr
Div. Yield (%)0.60
PE Ratio13.12
Debt to Equity0.04
Price to Book1.88
Book Value424.97
EPS (TTM)63.89
Face Value2.00
ROE (%)27.98

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
NATCOPHARMNSE
LTP
1W Low
1W High
Market cap (₹)
1899.7-20.3 (-1.06%)
1896.80
1984.80
4,56,833Cr
9133-106 (-1.15%)
9087
9467
2,45,426Cr
4841-209 (-4.14%)
4823
5066
1,87,320Cr
1129.5-61.5 (-5.16%)
1125.10
1187
1,13,217Cr
1380.2-43.3 (-3.04%)
1376
1426.10
1,12,212Cr
1844-94.5 (-4.87%)
1811.70
1949
1,01,155Cr
2109.1-62.4 (-2.87%)
2107.20
2192
97,626Cr
2330.9-52 (-2.18%)
2327.30
2419.20
96,859Cr
1157.9-20.1 (-1.71%)
1154.40
1179.90
96,406Cr
1652.7+7.4 (0.45%)
1622.60
1717
93,614Cr
831.05-22.75 (-2.66%)
829
863.40
15,010Cr

Key Highlights of Natco Pharma Ltd’s P&L

In 2025-03-31, Natco Pharma Ltd reported total revenue of ₹4786.2Cr, compared with ₹4126.9Cr in 2024-03-31, reflecting Natco Pharma Ltd turnover.

Depreciation was ₹235.2Cr and finance costs were ₹23.9Cr in 2025-03-31

Profit Before Tax (PBT) has been ₹2291.4Cr in 2025-03-31 as compared to ₹1673.5Cr in 2024-03-31.

Net Profit (PAT) was ₹1885.4Cr in 2025-03-31 compared with ₹1388.3Cr in 2024-03-31.

Earnings per share (EPS) were ₹105.33 in 2025-03-31, compared with ₹77.56 in 2024-03-31.